Search research articles
Contact Us
Filters
Showing results (371-380 of 590) with videos related to
Page
of 59
Sort By:
European Urology
|
August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial
Axel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
The Journal of Urology
|
December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer
Robert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
The Journal of Emergency Medicine
|
October 1, 2008
National study on the frequency, types, causes, and consequences of voluntarily reported emergency department medication errors
Julius Cuong Pham, Julie L Story, Rodney W Hicks, et al.
Clinical Genitourinary Cancer
|
August 10, 2021
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study
Neal D Shore, Raluca Ionescu-Ittu, François Laliberté, et al.
Journal of Medical Economics
|
July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)
Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
European Urology
|
October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring
Fred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy
|
September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
Neal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer
|
February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel
Andrew J Armstrong, Fred Saad, De Phung, et al.
BJU International
|
November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
The Journal of Biological Chemistry
|
October 12, 2000
Sds3 (suppressor of defective silencing 3) is an integral component of the yeast Sin3[middle dot]Rpd3 histone deacetylase complex and is required for histone deacetylase activity
T Lechner, M J Carrozza, Y Yu, et al.
Page
of 59
Search research articles
Search
Showing results (371-380 of 590) with videos related to
Sort By:
Page
of 59
European Urology
|
August 8, 2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial
Axel Heidenreich, Simon Chowdhury, Laurence Klotz, et al.
The Journal of Urology
|
December 21, 2012
An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer
Robert C Flanigan, Anthony J Polcari, Neil D Shore, et al.
The Journal of Emergency Medicine
|
October 1, 2008
National study on the frequency, types, causes, and consequences of voluntarily reported emergency department medication errors
Julius Cuong Pham, Julie L Story, Rodney W Hicks, et al.
Clinical Genitourinary Cancer
|
August 10, 2021
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study
Neal D Shore, Raluca Ionescu-Ittu, François Laliberté, et al.
Journal of Medical Economics
|
July 15, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023)
Mehmet A Bilen, Benjamin Lowentritt, Sabree Burbage, et al.
European Urology
|
October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring
Fred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy
|
September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
Neal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer
|
February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel
Andrew J Armstrong, Fred Saad, De Phung, et al.
BJU International
|
November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
Fritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
The Journal of Biological Chemistry
|
October 12, 2000
Sds3 (suppressor of defective silencing 3) is an integral component of the yeast Sin3[middle dot]Rpd3 histone deacetylase complex and is required for histone deacetylase activity
T Lechner, M J Carrozza, Y Yu, et al.
Page
of 59